Vermillion (NASDAQ:VRML) Stock Price Crosses Above 200-Day Moving Average of $0.73

Vermillion, Inc. (NASDAQ:VRML)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.73 and traded as high as $0.77. Vermillion shares last traded at $0.72, with a volume of 12,470 shares trading hands.

The company has a debt-to-equity ratio of 0.10, a current ratio of 4.54 and a quick ratio of 4.53. The stock’s 50-day simple moving average is $0.67 and its 200 day simple moving average is $0.73.

Vermillion (NASDAQ:VRML) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter. Vermillion had a negative return on equity of 163.08% and a negative net margin of 353.32%. The firm had revenue of $1.29 million for the quarter.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Magnus Financial Group LLC increased its holdings in Vermillion by 150.9% during the 2nd quarter. Magnus Financial Group LLC now owns 75,261 shares of the company’s stock valued at $67,000 after purchasing an additional 45,261 shares in the last quarter. CVI Holdings LLC bought a new position in Vermillion in the 2nd quarter valued at $71,000. Millennium Management LLC acquired a new position in Vermillion in the third quarter worth $78,000. Lincoln National Corp boosted its stake in Vermillion by 35.1% in the second quarter. Lincoln National Corp now owns 174,916 shares of the company’s stock worth $156,000 after purchasing an additional 45,455 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Vermillion in the second quarter worth $278,000. Institutional investors and hedge funds own 21.04% of the company’s stock.

About Vermillion (NASDAQ:VRML)

Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.

Featured Article: Trading based on a resistance level

Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with's FREE daily email newsletter.